Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Treasury Shares (2016 - 2024)

Historic Treasury Shares for Sangamo Therapeutics (SGMO) over the last 14 years, with Q4 2024 value amounting to $11.0 million.

  • Sangamo Therapeutics' Treasury Shares rose 8210.85% to $11.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $11.0 million, marking a year-over-year increase of 8210.85%. This contributed to the annual value of $11.0 million for FY2024, which is 8210.85% up from last year.
  • According to the latest figures from Q4 2024, Sangamo Therapeutics' Treasury Shares is $11.0 million, which was up 8210.85% from $6.1 million recorded in Q4 2023.
  • Sangamo Therapeutics' 5-year Treasury Shares high stood at $11.0 million for Q4 2024, and its period low was $2.7 million during Q4 2020.
  • Moreover, its 5-year median value for Treasury Shares was $5.2 million (2022), whereas its average is $5.6 million.
  • In the last 5 years, Sangamo Therapeutics' Treasury Shares surged by 20961.67% in 2020 and then surged by 1542.79% in 2023.
  • Quarter analysis of 5 years shows Sangamo Therapeutics' Treasury Shares stood at $2.7 million in 2020, then rose by 17.52% to $3.1 million in 2021, then soared by 67.02% to $5.2 million in 2022, then grew by 15.43% to $6.1 million in 2023, then skyrocketed by 82.11% to $11.0 million in 2024.
  • Its Treasury Shares stands at $11.0 million for Q4 2024, versus $6.1 million for Q4 2023 and $5.2 million for Q4 2022.